Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Leukemia - Overview - Disease Synopsis

Drugs & Clinical Candidates


50 drugs have received FDA approval for Leukemia . Alemtuzumab, Arsenic Trioxide, Asparaginase Erwinia chrysanthemi, Bendamustine Hydrochloride, Blinatumomab, Bosutinib Monohydrate, Busulfan, Calaspargase Pegol-mknl, Chlorambucil, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone Sodium Phosphate, Doxorubicin Hydrochloride, Duvelisib, Filgrastim, Fludarabine Phosphate, GILTERITINIB FUMARATE, Hydroxyurea, IVOSIDENIB, Ibrutinib, Idarubicin Hydrochloride, Idelalisib, Imatinib Mesylate, Inotuzumab Ozogamicin, Mechlorethamine Hydrochloride, Mercaptopurine, Methotrexate Sodium, Methoxymethane, Midostaurin, Mitoxantrone Hydrochloride, Moxetumomab Pasudotox-tdfk, Nelarabine, Nilotinib Hydrochloride Monohydrate, Obinutuzumab, Omacetaxine Mepesuccinate, Palifermin, Pegaspargase, Ponatinib Hydrochloride, Prednisolone Sodium Phosphate, Rasburicase, Recombinant Interferon Alfa-2b, Rituximab, Thioguanine, Tisagenlecleucel, Venetoclax and Vincristine Sulfate
536 drugs have a clinical trial registered for Leukemia.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 4957 clinical trials for Leukemia,
3473 of which have one or more drug interventions,
1484 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 1024 Cell Line Models for Leukemia.

Source: COSMIC
(see details)

Chemistry


There are 21881 Compounds which have been tested in Leukemia , 15570 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Leukemia:
Leukemia
Leukemia, B-Cell
Leukemia, Basophilic, Acute
Leukemia, Biphenotypic, Acute
Leukemia, Eosinophilic, Acute
Leukemia, Erythroblastic, Acute
Leukemia, Hairy Cell
Leukemia, Large Granular Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Mast-Cell
Leukemia, Megakaryoblastic, Acute
Leukemia, Monocytic, Acute
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myeloid, Acute
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Leukemia, Myeloid, Chronic-Phase
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Leukemia, Neutrophilic, Chronic
Leukemia, Plasma Cell
Leukemia, Prolymphocytic
Leukemia, Prolymphocytic, B-Cell
Leukemia, Prolymphocytic, T-Cell
Leukemia, Promyelocytic, Acute
Leukemia, T-Cell
Preleukemia

The following terms have been mapped from cancer.gov to Leukemia:
Acute leukemia
Acute lymphoblastic leukemia (ALL)
Acute lymphoblastic leukemia (ALL) in children
Acute lymphoblastic leukemia (ALL). It is used as maintenance therapy in adults and children
Acute lymphoblastic leukemia (ALL). It is used:As first-line treatment
Acute lymphoblastic leukemia in adults and children
Acute lymphoblastic leukemia in adults and children that is Philadelphia chromosome positive. In adults, it is used for disease that has recurred (come back) or is refractory (does not respond to treatment). In children, it is used as the first treatment after the disease is diagnosed
Acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is used with combination chemotherapy
Acute lymphoblastic leukemia that has recurred (come back) or is refractory (does not respond to treatment) in children who have already had at least two other types of treatment
Acute lymphoblastic leukemia that has spread to the central nervous system, or to prevent it from spreading there
Acute lymphoblastic leukemia that is Philadelphia chromosome negative. It is used in patients whose disease has relapsed two or more times or has not gotten better with two or more types of treatment
Acute lymphoblastic leukemia that is Philadelphia chromosome positive and has the T315I mutation
Acute lymphoblastic leukemia that is Philadelphia chromosome positive. It is used in adults whose disease did not respond to other drugs or who are not able to use other drugs
Acute lymphoblastic leukemia. It is a form of asparaginase made from the bacterium Erwinia chrysanthemi. It is used in patients who can no longer take asparaginase made from E. coli
Acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adult patients whose AML has a certain mutation in the isocitrate dehydrogenase-1 (IDH1) gene
Acute myeloid leukemia (AML) that is newly diagnosed. It is used in patients with therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC)
Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene
Acute myeloid leukemia in adults
Acute myeloid leukemia that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults whose cancer has a mutation in the FLT3 gene
Acute myeloid leukemia that is newly diagnosed. It is used in patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy. It is given with either azacitidine, decitabine, or low-dose cytarabine
Acute promyelocytic leukemia (APL) in patients whose cancer has a certain type of chromosome mutation that affects the PML gene and RARA gene. It is used:In adults with newly diagnosed APL that is low risk
Aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia in adults
B-cell acute lymphoblastic leukemia (ALL) that has relapsed or is refractory (does not respond to treatment)
B-cell acute lymphoblastic leukemia in adults and children. It is used:In patients whose cancer has recurred (come back) or is refractory (does not respond to treatment)
B-cell acute lymphoblastic leukemia. It is used in children and adults up to 25 years old whose disease is refractory (does not respond to treatment) or has relapsed two or more times
B-cell chronic lymphocytic leukemia (CLL)
Chronic eosinophilic leukemia or hypereosinophilic syndrome
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia (CLL) in adults. It is used with fludarabine phosphate and cyclophosphamide
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is used in patients who have already received at least one type of treatment
Chronic lymphocytic leukemia (CLL) that has recurred (come back). It is used with rituximab in patients who are able to be treated with rituximab alone
Chronic lymphocytic leukemia (CLL). It is used in patients with B-cell CLL
Chronic lymphocytic leukemia (CLL). It is used with chlorambucil in patients who have not yet been treated for CLL
Chronic lymphocytic leukemia (CLL). This use is approved for the Rituxan brand of rituximab
Chronic lymphocytic leukemia (CLL).It is used alone as extended treatment in patients with recurrent or progressive disease who are in complete or partial response after at least two other types of treatment
Chronic lymphocytic leukemia and small lymphocytic lymphoma
Chronic lymphocytic leukemia or small lymphocytic lymphoma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least two other therapies
Chronic myelogenous leukemia (CML)
Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used: In adults with newly diagnosed chronic phase CML. This use is approved under FDA??????s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that bosutinib provides a clinical benefit in these patients
Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:In adults and children aged 1 year or older with newly diagnosed chronic phase CML
Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:In children with chronic phase CML
Chronic myelogenous leukemia (CML). It is used as palliative treatment. It is also used with other drugs to prepare patients with CML for a stem cell transplant
Chronic myelogenous leukemia that has the T315I mutation
Chronic myelogenous leukemia that is Philadelphia chromosome positive
Chronic myelogenous leukemia that is refractory (does not respond to treatment)
Chronic myelogenous leukemia. It is used in some patients who have been treated with at least two drugs called tyrosine kinase inhibitors and have not gotten better
Hairy cell leukemia
Hairy cell leukemia in adults
Hairy cell leukemia that has relapsed or is refractory (does not respond to treatment). It is used in adults who have been treated with at least two systemic therapies, including a purine nucleoside analog
Leukemia
Meningeal leukemia (leukemia that has spread to the meninges). It is given as intrathecal therapy
Neutropenia caused by some types of chemotherapy, including:Chemotherapy for acute myeloid leukemia
Oral mucositis that is severe. It is used in patients with leukemia or lymphoma who are being treated with high-dose chemotherapy and radiation therapy, followed by stem cell rescue
T-cell acute lymphoblastic leukemia
Tumor lysis syndrome in patients with leukemia, lymphoma, or malignant solid tumors. It is used when the treatment is expected to cause high blood levels of uric acid